Luca De Carolis
Perugia, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R).
Journal: HemaSphere
Published: September 08, 2025
An unusual form of BRAF-V600E mutated hairy cell neoplasm with clinical resistance to BRAF inhibition: Challenging precision medicine.
Journal: American journal of hematology
Published: August 28, 2023
Venetoclax in Relapsed or Refractory Hairy-Cell Leukemia.
Journal: The New England journal of medicine
Published: March 08, 2023
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia.
Journal: British journal of haematology
Published: September 29, 2022
Choroidal vasculature analysis in MEK inhibitor-associated retinopathy.
Journal: European journal of ophthalmology
Published: February 23, 2022
How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
Journal: Blood
Published: August 11, 2021
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
Journal: The New England journal of medicine
Published: May 12, 2021
Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial.
Journal: Leukemia
Published: November 19, 2020
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
Journal: The New England journal of medicine
Published: September 10, 2015
Showing 1-11 of 11
Last Updated: 09/26/2026